Actively Recruiting
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
Led by University Health Network, Toronto · Updated on 2024-12-16
48
Participants Needed
2
Research Sites
495 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation. The main questions it aims to answer are: * How many patients will achieve transplant with this treatment strategy? * What will the 5-year survival and recurrence-free survival rates be for these patients? Participants will: * Undergo a biopsy of the tumor. * Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months. * Be referred for a liver transplant and undergo the procedure if deemed eligible and safe. * If applicable, be followed for five years post-transplant with regular data collection.
CONDITIONS
Official Title
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 70 years
- Weight greater than 30 kg
- Child Pugh Turcotte score between A5 and B7
- Presence of macrovascular invasion classified as Vp1 to Vp3
- Total tumor volume less than 350 cm3
- Alpha fetoprotein (AFP) less than 5000 ng/mL
- No evidence of extrahepatic disease
- No other contraindications for liver transplantation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Ability to provide informed consent
- Radiological and histological confirmation of hepatocellular carcinoma
You will not qualify if you...
- Poorly differentiated hepatocellular carcinoma
- Prior therapy for hepatocellular carcinoma other than liver resection or ablation
- Portal vein tumor thrombus extending beyond the main portal vein
- Obesity class III with body mass index (BMI) 40 kg/m2 or higher
- Contraindications to radiotherapy (Y90 or SBRT) or treatment with Atezolizumab and Bevacizumab
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
Not Yet Recruiting
2
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
Research Team
C
Clinical Research Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here